Check Before You Invest : Par Drugs And Chemicals Ltd

Snapshot

Q.1 Which industry/sub-sector does Par Drugs And Chemicals Ltd belong to?

Par Drugs And Chemicals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Par Drugs And Chemicals Ltd a good quality company?

Par Drugs And Chemicals Ltd is a good quality company, based on a consistently good 10 year financial track record.

Q.3 Is Par Drugs And Chemicals Ltd undervalued or overvalued?

Par Drugs And Chemicals Ltd appears Undervalued, as its key valuation ratios are below with their past averages.

Q.4 Is Par Drugs And Chemicals Ltd a good buy now?

Par Drugs And Chemicals Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd revenue growth is 5.6% for FY-2025 , which is below its 5 year CAGR of 12.6% , indicating slower growth.

Q.2 Gross Profit margin of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd Gross profit margin which is the profit after deduction of direct costs, is 19% for FY-2025 , which is in line with its 5 year median of 19% , indicating stable margins.

Q.3 Operating Profit Margin of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 19.31% for FY-2025 , which is below its 5 year median of 21.65% indicating decreasing margins.

Q.4 Net Profit Margin of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd Net Profit Margin is 13.23% for FY-2025 , is in line with with its 5 year median of 13.23%, indicating stable margins.

	Current Level	Historic Median
Gross Profit Margin	19	19
Operating Profit Margin	19.31	21.65
Net Profit Margin	13.23	13.23

Q.5 Return on Asset of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd Return on Asset is 12.09%, which is below its 5 year historical median of 13.53%, indicating deteriorated asset utilization efficiency.

Q.6 Return on Equity (ROE) of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd Return on equity is 14.47% for FY-2025 , which is below its historical median of 17.29%, indicating the business is making worse use of its shareholders capital.

Q.7 Return on capital employed (ROCE) of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd Return on capital employed is 19.51% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.

Q.8 Cash conversion cycle of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd Cash conversion cycle is 30 days, below its historical median of 32 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.

	Current Level	Historic Median
Asset Turnover	1.03	1.09
ROE	14.47	17.29
ROCE	19.51	23.2
Cash Conversion Cycle	30 days	32 days

Q.9 Debt to Equity ratio of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.

Q.10 Debt to cash flow from operations of Par Drugs And Chemicals Ltd?

Par Drugs And Chemicals Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Par Drugs And Chemicals Ltd?

Promoters hold 73.41% of the Par Drugs And Chemicals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Par Drugs And Chemicals Ltd vs industry peers?

Par Drugs And Chemicals Ltd revenue CAGR is 12.57% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.

Profit Metrics

	Current Level	Industry Median
Revenue	101	137.1
Gross Profit	19.2	15.1
Operating Profit	20	16
Net Profit	13	5.6

Operating Efficiency

	Current Level	Industry Median
Asset Turnover	1.03	0.8
ROE	14.47	8.91
ROCE	19.51	11.59
Cash Conversion Cycle (days)	30.4	76

Valuation & price assessment

Q.1 Stock return of Par Drugs And Chemicals Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of -5.65% based on the current price.

Q.2 What return has the stock given over the last decade?

	9Y	5Y	3Y	1Y
Share Price	-	-5.7%	-14.2%	-6.6%

Q.3 Valuation ratios of Par Drugs And Chemicals Ltd vs historical?

The current P/E is higher that its historical median.

Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?

Valuation Ratios	Current	Historic Median	Industry Median
Price to Earnings	8.27	0.00	40.28
Price to Book	1.03	3.53	2.77
Price to Sales	1.08	2.73	2.65
EV to EBITDA	3.6	0.00	15.67

Check more companies

5. Wockhardt

6. Pfizer

7. Astrazeneca Pharma I

8. Sai Life Sciences

9. Natco Pharma

10. Eris Lifesciences

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Check Before You Invest : Par Drugs And Chemicals Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.